Abstract
Autoantibodies neutralising the effect of the bone regulatory cytokine osteoprotegerin (OPG) have been described in a patient with severe osteoporosis and coeliac disease. This study aimed to determine the prevalence and epitope specificity of autoantibodies to OPG in patients with coeliac disease, and correlate their presence with bone mineral density. A direct enzyme-linked immunosorbent assay was developed and used to screen patients with coeliac disease for autoantibodies to OPG. Recombinant fragments of OPG were made to evaluate the epitope specificity and affinity of these antibodies. Phenotype information of the patients was obtained by case note review. Raised titres of antibodies to OPG were found in 7/71 (9.8 %) patients with coeliac disease, compared with 1/72 (1.4 %) non-coeliac osteoporosis clinic control patients (p < 0.05). Our results suggest that a polyclonal antibody response to OPG is raised in these patients capable of recognising different epitopes of OPG with varying affinity. The titre of OPG antibodies was associated with lower bone mineral density Z-score of the hip in coeliac patients on univariate (p < 0.05) and multivariate analysis including age, sex height and weight as covariates (p < 0.01). Polyclonal antibodies to OPG are more common in patients with coeliac disease and are independently associated with lower bone mineral density Z-scores of the hip. Further work is required to establish the clinical utility of testing for OPG antibodies.
Similar content being viewed by others
References
Browne SK, Holland SM (2010) Immunodeficiency secondary to anticytokine autoantibodies. Curr Opin Allergy Clin Immunol 10:534–541
Riches PL, McRorie E, Fraser WD, Determann C, Hof Rv, Ralston SH (2009) Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin. N Engl J Med 361:1459–1465
Boyce BF, Xing L (2007) The RANKL/RANK/OPG pathway. Curr Osteoporos Rep 5:98–104
Khosla S (2001) Minireview: the OPG/RANKL/RANK System. Endocrinology 142:5050–5055
Riches PL, Ralston SH (2010) Recent insights into the biology of bone turnover. J R Coll Phys Edinb 40:66–69
McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831
Chong B, Hegde M, Fawkner M, Simonet S, Cassinelli H, Coker M, Kanis J, Seidel J, Tau C, Tuysuz B, Yuksel B, Love D, Cundy T (2003) Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J Bone Miner Res 18:2095–2104
Goldring SR, Gravallese EM (2000) Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Res 2:33–37
Bianchi ML, Bardella MT (2002) Bone and celiac disease. Calcif Tiss Int 71:465–471
Meyer D, Stavropolous S, Diamond B, Shane E, Green PHR (2001) Osteoporosis in a North American adult population with celiac disease. Am J Gastroenterol 96:112–119
Pazianas M, Butcher GP, Subhani JM, Finch PJ, Ang L, Collins C, Heaney RP, Zaidi M, Maxwell JD (2005) Calcium absorption and bone mineral density in celiacs after long term treatment with gluten-free diet and adequate calcium intake. Osteoporos Int 16:56–63
Taranta A, Fortunati D, Longo M, Rucci N, Iacomino E, Aliberti F, Facciuto E, Migliaccio S, Bardella MT, Dubini A, Borghi MO, Saraifoger S, Teti A, Bianchi ML (2004) Imbalance of osteoclastogenesis-regulating factors in patients with celiac disease. J Bone Miner Res 19:1112–1121
Corazza GR, Di SM, Maurino E, Bai JC (2005) Bones in coeliac disease: diagnosis and treatment. Best Pract Res Clin Gastroenterol 19:453–465
Schousboe JT, Shepherd JA, Bilezikian JP, Baim S (2013) 2013 executive summary of the 2013 ISCD position development conference on bone densitometry. J Clin Densitom 16:455–467
Luan X, Lu Q, Jiang Y, Zhang S, Wang Q, Yuan H, Zhao W, Wang J, Wang X (2012) Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin. J Immunol 189:245–252
Schneeweis LA, Willard D, Milla ME (2005) Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. J Biol Chem 280:41155–41164
Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E, Morinaga T, Higashio K (1998) Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 273:5117–5123
Nagele EP, Han M, Acharya NK, DeMarshall C, Kosciuk MC, Nagele RG (2013) Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease. PLoS ONE 8:e60726
Panda S, Ding JL (2015) Natural antibodies bridge innate and adaptive immunity. J Immunol 194:13–20
Larussa T, Suraci E, Nazionale I, Leone I, Montalcini T, Abenavoli L, Imeneo M, Pujia A, Luzza F (2012) No evidence of circulating autoantibodies against osteoprotegerin in patients with celiac disease. World J Gastroenterol 14:1622–1627
Denham JM, Hill ID (2013) Celiac disease and autoimmunity: review and controversies. Curr Allergy Asthma Rep 13:347–353
Hauser B, Riches PL, Gilchrist T, Visconti MR, Wilson JF, Ralston SH (2015) Autoantibodies to osteoprotegerin are associated with increased bone resorption in rheumatoid arthritis. Ann Rheum Dis. doi:10.1136/annrheumdis-2014-207219
Acknowledgments
The authors would like to acknowledge the generous support of Coeliac UK/Core in funding this work.
Conflict of Interest
PLR, SHR and WDF have a patent application pending relating to the detection of osteoprotegerin antibodies in the diagnosis of osteoporosis. PLR reports Grants from ECTS and CSO during the conduct of the study; personal fees from IDS and a Grant from Menarini outside the submitted work. SHR reports Grants from Arthritis Research UK during the conduct of the study, consultancy fees from Merck and Novartis, Grants from Amgen and Eli Lilly and Company outside the submitted work. WDF reports fees from IDS, and Grants from Roche, Abbott, Siemens and Neotrix outside the submitted work. JS reports personal fees from Takeda, MSD and Shire outside the submitted work. NK reports Grants from Wellcome Trust outside the submitted work. All remaining authors have no disclosures.
Human and Animal Rights and Informed Consent
The study was approved by Lothian Research Ethics Committee, with all participants giving informed consent.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Real, A., Gilbert, N., Hauser, B. et al. Characterisation of Osteoprotegerin Autoantibodies in Coeliac Disease. Calcif Tissue Int 97, 125–133 (2015). https://doi.org/10.1007/s00223-015-0023-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00223-015-0023-4